Evidence map›Paper›PMID 41181103›Full record

ArticleFrontiers in immunology2025

Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h.

Daniel Munárriz, Luis Gerardo Rodríguez-Lobato, Lucía López-Corral, Cristina Arnaldos-Pérez, Valentín Cabañas, Nieves López-Muñoz, Aina Oliver-Caldés, Juan Carlos Ponce, Juan Luis Reguera, Ana África Martín and 13 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Daniel MunárrizHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Luis Gerardo Rodríguez-LobatoHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Lucía López-CorralUniversity Hospital of Salamanca, Biomedical Research Institute of Salamanca Instituto de Investigación Biomédica de Salamanca, Cancer Research Center Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC) , Salamanca, Spain.
Cristina Arnaldos-PérezHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Valentín CabañasVirgen de la Arrixaca University Clinical Hospital, Instituto Murciano de Investigación Biosanitaria-Arrixaca, University of Murcia, Murcia, Spain.
Nieves López-MuñozUniversity Hospital 12 de Octubre, Complutense University, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
Aina Oliver-CaldésHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Juan Carlos PonceUniversity Clinic of Navarra, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red (CIBERONC) CB16/12/00369, Pamplona, Spain.
Juan Luis RegueraVirgen del Rocío University Hospital, Institute of Biomedicine of Seville (IBIS/CSIC/Centro de Investigación Biomédica en Red (CIBERONC)), University of Seville, Seville, Spain.
Ana África MartínUniversity Hospital of Salamanca, Biomedical Research Institute of Salamanca Instituto de Investigación Biomédica de Salamanca, Cancer Research Center Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC) , Salamanca, Spain.
Núria Martínez-CibriánHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Natalia TovarHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Julio DelgadoHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Elena GuillenHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Sara VareaHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Paula Rodríguez-OteroUniversity Clinic of Navarra, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red (CIBERONC) CB16/12/00369, Pamplona, Spain.
Álvaro Urbano-IspizuaHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
José María MoraledaVirgen de la Arrixaca University Clinical Hospital, Instituto Murciano de Investigación Biosanitaria-Arrixaca, University of Murcia, Murcia, Spain.
Joaquín Martínez-LópezUniversity Hospital 12 de Octubre, Complutense University, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
María-Victoria MateosUniversity Hospital of Salamanca, Biomedical Research Institute of Salamanca Instituto de Investigación Biomédica de Salamanca, Cancer Research Center Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC) , Salamanca, Spain.
Verónica González De la CalleUniversity Hospital of Salamanca, Biomedical Research Institute of Salamanca Instituto de Investigación Biomédica de Salamanca, Cancer Research Center Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Consejo Superior de Investigaciones Científicas (CSIC) , Salamanca, Spain.
Europa Azucena González-NavarroHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Carlos Fernández de LarreaHospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized multiple myeloma treatment (MM). However, managing its immune-mediated adverse events, particularly macrophage activation syndrome- Methods: This multicentre, retrospective, analytical study evaluated MM patients treated with the anti-BCMA academic product ARI0002h. MAS- Results: Of 80 patients, 12 (15%) met the UCSF criteria for MAS- Conclusions: MAS-

Indexed as

B-Cell Maturation AntigenImmunotherapy, AdoptiveMacrophage Activation SyndromeMultiple MyelomaReceptors, Chimeric AntigenAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeB-Cell Maturation AntigenReceptors, Chimeric AntigenTNFRSF17 protein, humananti-BCMA CAR TIEC-HSimmunotherapyMAS-like syndromemyeloma

Identifiers

PMID41181103
PMCPMC12571847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.